[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Fottner A, Szalantzy M, Wirthmann L, Stähler M, Baur-Melnyk A, Jansson V, Dürr HR: Bone metastases from renal cell carcinoma: patient survival after surgical treatment. BMC Musculoskelet Disord; 2010;11:145
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone metastases from renal cell carcinoma: patient survival after surgical treatment.
  • BACKGROUND: Surgery is the primary treatment of skeletal metastases from renal cell carcinoma, because radiation and chemotherapy frequently are not effecting the survival.
  • We therefore explored factors potentially affecting the survival of patients after surgical treatment.
  • RESULTS: 27 patients had a solitary bone metastasis, 20 patients multiple bone metastases and 54 patients had concomitant visceral metastases.
  • Patients with solitary bone metastases had a better survival (p < 0.001) compared to patients with multiple metastases.
  • Age younger than 65 years (p = 0.036), absence of pathologic fractures (p < 0.001) and tumor-free resection margins (p = 0.028) predicted higher survival.
  • Gender, location of metastases, time between diagnosis of renal cell carcinoma and treatment of metastatic disease, incidence of local recurrence, radiation and chemotherapy did not influence survival.
  • As radiation and chemotherapy are ineffective in most patients, surgery is a better option to achieve local tumor control and increase the survival.
  • [MeSH-major] Bone Neoplasms / mortality. Bone Neoplasms / secondary. Carcinoma, Renal Cell / mortality. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / secondary
  • [MeSH-minor] Age Distribution. Age Factors. Aged. Disease Progression. Female. Fractures, Bone / epidemiology. Fractures, Bone / pathology. Fractures, Bone / physiopathology. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / physiopathology. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / surgery. Prognosis. Retrospective Studies. Severity of Illness Index. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Orthop Ihre Grenzgeb. 2006 Jan-Feb;144(1):58-67 [16498562.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1894-900 [16177996.001]
  • [Cites] Clin Orthop Relat Res. 2007 Jun;459:133-8 [17438472.001]
  • [Cites] J Bone Joint Surg Am. 2007 Aug;89(8):1794-801 [17671020.001]
  • [Cites] Clin Orthop Relat Res. 1999 Oct;(367):283-90 [10546626.001]
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):62-7 [10697316.001]
  • [Cites] Semin Oncol. 2000 Apr;27(2):115-23 [10768591.001]
  • [Cites] Semin Oncol. 2000 Apr;27(2):160-76 [10768595.001]
  • [Cites] J Urol. 2000 Nov;164(5):1505-8 [11025692.001]
  • [Cites] Int J Oncol. 2001 Aug;19(2):379-82 [11445855.001]
  • [Cites] J Bone Joint Surg Br. 2002 May;84(4):521-9 [12043772.001]
  • [Cites] Urology. 2003 Feb;61(2):314-9 [12597937.001]
  • [Cites] Clin Orthop Relat Res. 2003 Apr;(409):223-31 [12671506.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3316-22 [15310775.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6302S-3S [15448021.001]
  • [Cites] J Urol. 1975 Jul;114(1):27-9 [1142493.001]
  • [Cites] Urology. 1978 Jun;11(6):563-7 [675922.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Urology. 1981 Dec;18(6):556-61 [7314355.001]
  • [Cites] Acta Orthop Scand. 1984 Oct;55(5):491-500 [6507069.001]
  • [Cites] J Urol. 1988 Aug;140(2):277-9 [3398121.001]
  • [Cites] Jpn J Clin Oncol. 1989 Jun;19(2):142-8 [2733167.001]
  • [Cites] J Surg Oncol. 1992 Jan;49(1):45-8 [1548881.001]
  • [Cites] J Urol. 1992 Sep;148(3):784-7 [1512825.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1103-9 [9305711.001]
  • [Cites] JAMA. 1999 May 5;281(17):1628-31 [10235157.001]
  • [Cites] Scand J Urol Nephrol. 2004;38(4):299-305 [15669589.001]
  • [Cites] Clin Orthop Relat Res. 2005 Feb;(431):187-92 [15685074.001]
  • [Cites] Eur Urol. 2007 Jul;52(1):163-8 [17098353.001]
  • (PMID = 20598157.001).
  • [ISSN] 1471-2474
  • [Journal-full-title] BMC musculoskeletal disorders
  • [ISO-abbreviation] BMC Musculoskelet Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2909163
  •  go-up   go-down


2. Weisskopf M, Münker R, Hermanns-Sachweh B, Ohnsorge JA, Siebert C: Epithelioid sarcoma in the thoracic spine. Eur Spine J; 2006 Oct;15 Suppl 5:604-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelioid sarcoma is a rare and highly malignant soft tissue tumor that is commonly found in the extremities and rarely in the trunk area.
  • This malignant tumor often mimics granuloma or nodular fasciitis, which causes a delay in establishing the diagnosis.
  • This type of cancer has a high recurrence rate.
  • Surgical treatment requires wide radical resection.
  • The objective of this case report is to highlight the unique location of a rare neoplasm and to illustrate the relentless course of epithelioid sarcoma despite initial radical resection.
  • A 14-year-old boy was admitted to our facility with a soft tissue mass on the right lower thoracic spine.
  • The large tumor mass had deeply penetrated into the muscles, infiltrated the neuroforamen of T9-T10 level, and compressed the dural sac.
  • The patient received chemotherapy and irradiation.
  • The first recurrence of the neoplasm was seen as a contralateral metastasis 21 months after the resection.
  • Initial wide excision of the neoplasm and adjuvant therapy including chemotherapy and irradiation seem to slow down the relentless course of epithelioid sarcoma in the trunk.
  • [MeSH-major] Orthopedic Procedures. Sarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis. Spinal Neoplasms / diagnosis. Thoracic Vertebrae
  • [MeSH-minor] Adolescent. Biopsy. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Orthopedic Fixation Devices. Positron-Emission Tomography. Postoperative Period. Radiography, Thoracic. Spinal Fusion

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Orthop. 2002;26(1):26-30 [11954844.001]
  • [Cites] Radiology. 2004 Mar;230(3):697-702 [14749514.001]
  • [Cites] Cancer. 1970 Nov;26(5):1029-41 [5476785.001]
  • [Cites] Pol Med J. 1971;10(1):12-7 [5573897.001]
  • [Cites] Cancer. 1972 Jul;30(1):128-43 [4339255.001]
  • [Cites] Cancer. 1972 Aug;30(2):486-99 [4340662.001]
  • [Cites] Ann Surg Oncol. 1997 Sep;4(6):491-5 [9309338.001]
  • [Cites] Cancer. 1978 Apr;41(4):1472-87 [639005.001]
  • [Cites] Am J Surg Pathol. 1985 Apr;9(4):241-63 [4014539.001]
  • [Cites] J Bone Joint Surg Am. 1988 Jul;70(6):862-70 [3392084.001]
  • [Cites] Eur J Surg Oncol. 1989 Aug;15(4):345-9 [2759252.001]
  • [Cites] J Pediatr Surg. 1994 Sep;29(9):1189-91 [7807342.001]
  • [Cites] Spine (Phila Pa 1976). 1996 Mar 1;21(5):634-8 [8852321.001]
  • [Cites] Cancer. 1977 Jan;39(1):143-52 [188535.001]
  • (PMID = 16474944.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC1602205
  •  go-up   go-down


3. Sawamura C, Springfield DS, Marcus KJ, Perez-Atayde AR, Gebhardt MC: Factors predicting local recurrence, metastasis, and survival in pediatric soft tissue sarcoma in extremities. Clin Orthop Relat Res; 2010 Nov;468(11):3019-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predicting local recurrence, metastasis, and survival in pediatric soft tissue sarcoma in extremities.
  • BACKGROUND: Pediatric soft tissue sarcomas are rare and differ from those in adults regarding the spectrum of diagnoses and treatment.
  • QUESTIONS/PURPOSES: We sought risk factors predicting local recurrence, metastasis, and overall survival and asked whether radiation and chemotherapy influenced local recurrence, metastasis, and overall survival.
  • METHODS: We retrospectively reviewed all 98 patients aged 18 years or younger diagnosed with soft tissue sarcomas in extremities from 1990 to 2008.
  • Age, tumor size, depth, location, bone or neurovascular involvement, histologic subtypes, unplanned excision, surgical margins, metastasis at diagnosis, and adjuvant treatments were reviewed for each patient.
  • RESULTS: Ninety-four patients underwent surgical excision and seven patients had local recurrence at a median time of 18.6 months.
  • Radiation therapy reduced the rate of local recurrence.
  • Fourteen patients had metastasis at diagnosis and seven patients later developed metastasis.
  • The median time to metastasis was 20.9 months.
  • Six patients died and the median time to death was 28.0 months.
  • Metastasis at diagnosis was a predictive factor for death.
  • CONCLUSIONS: When limited to extremities, radiation therapy reduced the rate of local recurrence in pediatric soft tissue sarcomas.
  • Metastases at diagnosis predict death.
  • [MeSH-major] Neoplasm Recurrence, Local / prevention & control. Orthopedic Procedures. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Age Factors. Amputation. Boston. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Extremities. Female. Humans. Infant. Infant, Newborn. Limb Salvage. Male. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Risk Factors. Survival Rate. Time Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3697-705 [10577841.001]
  • [Cites] Cancer. 2009 Aug 1;115(15):3537-47 [19514087.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3225-35 [12149295.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):571-80 [12879475.001]
  • [Cites] J Bone Joint Surg Am. 1989 Mar;71(3):370-5 [2925710.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1119-29 [2302663.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):646-52 [9053489.001]
  • [Cites] Pediatr Clin North Am. 1997 Aug;44(4):953-72 [9286294.001]
  • [Cites] J Pediatr. 1997 Oct;131(4):603-7 [9386667.001]
  • [Cites] J Pediatr Surg. 1999 May;34(5):672-5 [10359161.001]
  • [Cites] Acta Orthop Scand Suppl. 1999 Jun;285:45-6 [10429621.001]
  • [Cites] Clin Orthop Relat Res. 2007 Sep;462:181-9 [17534186.001]
  • [Cites] Surg Clin North Am. 2008 Jun;88(3):615-27, vii [18514702.001]
  • [Cites] Cancer. 2008 Jul 15;113(2):411-8 [18506733.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):573-81 [18521899.001]
  • [Cites] Cancer. 2008 Nov 1;113(9):2575-96 [18837040.001]
  • [Cites] Cancer. 2009 Jul 1;115(13):2988-98 [19452538.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3391-7 [19398574.001]
  • [Cites] Ann Surg. 2000 May;231(5):655-63 [10767786.001]
  • (PMID = 20544321.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2947691
  •  go-up   go-down


Advertisement
4. Hartmann JT, Einhorn L, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Schmoll HJ, Kanz L, Bokemeyer C: Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol; 2001 Mar 15;19(6):1641-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis.
  • PURPOSE: Relapsed extragonadal germ cell tumors patients (EGGCT) are treated with identical salvage chemotherapy regimens, as are patients with metastatic testicular cancer.
  • This investigation evaluates the results of second-line chemotherapy in nonseminomatous EGGCT and tries to identify prognostic factors for survival.
  • All had received cisplatin-containing regimens as induction treatment.
  • Median follow-up since start of salvage treatment was 11 months (range, 1 to 157) for all patients and 45 months (range, 6 to 157) for surviving patients.
  • Forty-eight patients (34%) received high dose chemotherapy with autologous bone marrow transplant at relapse, and 10 of these patients (21%) are continuously disease-free.
  • Primary mediastinal location (P =.003), sensitivity to cisplatin (P =.003), elevated beta-HCG at relapse (P: =.04), and normal LDH at diagnosis (P =.01) were shown to be significant negative prognostic factors for overall survival in univariate; mediastinal location [relative risk ratios (HR) = 1.9; 95% confidence intervals (CI), 1.2 to 3.0] and sensitivity to cisplatin [HR = 2.4; 95% CI, 1.1 to 5.2] were significant negative prognostic factors in multivariate analysis.
  • CONCLUSION: Although current salvage strategies will cure between 20% and 50% of recurrent metastatic testicular cancer, relapsed nonseminomatous EGGCT patients appear to have an inferior survival rate, in particular in case of primary mediastinal location.
  • Mediastinal primary tumor and inadequate response to cisplatin-based induction chemotherapy have been identified as independent negative prognostic factors, both associated with an approximately two-fold higher risk for failure of salvage treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mediastinal Neoplasms / drug therapy. Neoplasms, Germ Cell and Embryonal / drug therapy. Retroperitoneal Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / administration & dosage. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Risk Factors. Salvage Therapy. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11250992.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Kim MS, Lee SY, Lee TR, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Jeon DG: Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol; 2009 May;20(5):955-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma.
  • BACKGROUND: In this retrospective study, we developed and internally validate a nomogram for predicting 5-year metastasis probability for nonmetastatic extremity osteosarcoma.
  • Multivariate Cox model identified patient age at diagnosis, tumor size, humeral location, and tumor necrosis rate after chemotherapy as correlated with metastasis-free survival.
  • The degree of contribution of each covariate to the total point was tumor location, tumor necrosis rate, maximal tumor diameter, and age in decreasing order.
  • CONCLUSIONS: We devised a nomogram for nonmetastatic osteosarcoma that proposes improved estimates of metastasis over AJCC staging system or tumor necrosis rate.
  • We suggest that this nomogram allows individualized risk assessments and could be used as the basis for risk-adapted therapy.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19153123.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P, Forni C, Manfrini M, Donati D, Picci P: Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol; 2000 Jan;18(1):4-11
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.
  • PURPOSE: The identification of prognostic factors in patients with nonmetastatic Ewing's sarcoma could allow the use of risk-adapted therapeutic strategies of treatment.
  • PATIENTS AND METHODS: Data on 359 patients with nonmetastatic Ewing's sarcoma of bone treated at a single institution between January 1979 and April 1995 were retrospectively considered.
  • The influence of clinical, hematologic, therapeutic, and histologic parameters on event-free survival was assessed.
  • RESULTS: By univariate analysis, the following features were found to be associated with a poor prognosis: male sex (P <.02), age older than 12 years (P <.006), fever (P <.0001), anemia (P <.0025), high serum lactate dehydrogenase (LDH) level (P <.0001), axial location (P <.04), radiation therapy only for local control (P <.009), type of chemotherapy regimen (P <.0001), and poor chemotherapy-induced necrosis (P <.001).
  • After multivariate analysis, the adverse independent prognostic factors were male sex (P <.04), age older than 12 years (P <.001), fever (P <.0002), anemia (P <.02), high serum LDH level (P <.0003), axial location (P <.02), and type of chemotherapy regimen (P <.0003).
  • When the multivariate analysis was restricted to surgically treated patients, the adverse independent prognostic factors were poor chemotherapy-induced necrosis (P <.0001), fever (P <.015), anemia (P <.02), and high serum LDH level (P <.025).
  • In surgically treated patients, the most important prognostic factor is chemotherapy-induced necrosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / diagnosis. Bone Neoplasms / drug therapy. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / drug therapy
  • [MeSH-minor] Adolescent. Adult. Analysis of Variance. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant / methods. Child. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Italy / epidemiology. L-Lactate Dehydrogenase / blood. Male. Neoplasm Recurrence, Local. Prognosis. Proportional Hazards Models. Retrospective Studies. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10623687.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


7. Basu S, Baghel NS, Puri A, Shet T, Merchant NH: 18 F-FDG avid lesion due to coexistent fibrous dysplasia in a child of embryonal rhabdomyosarcoma: source of false positive FDG-PET. J Cancer Res Ther; 2010 Jan-Mar;6(1):92-4
Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With increasing use of 18 F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in the current oncological practice, there is a growing body of evidence of false positive scans due to various benign conditions.
  • The patient was a case of ERMS (presenting with left cervical mass with intrathoracic extension) who was treated successfully with chemotherapy and was referred for FDG-PET to evaluate the disease status.
  • The scan was extended up to foot in view of the fact that a prior bone scan had shown a focal uptake in the similar location.
  • The computed tomography (CT) scan of the same region showed cortical thickening and increased density within the medullary cavity in the shaft of the tibia.
  • A histopathological diagnosis was sought for and the lesion was subsequently proven to be fibrous dysplasia by histopathology of the bone piece obtained from the right tibial lesion by J needle biopsy.
  • [MeSH-major] Fibrous Dysplasia of Bone / radionuclide imaging. Fluorodeoxyglucose F18. Radiopharmaceuticals. Rhabdomyosarcoma, Embryonal / radionuclide imaging. Soft Tissue Neoplasms / radionuclide imaging
  • [MeSH-minor] Child. False Positive Reactions. Humans. Male. Neoplasm Metastasis / pathology. Positron-Emission Tomography. Tibia / pathology

  • Genetic Alliance. consumer health - Fibrous Dysplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479556.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


8. Shah JP, Gil Z: Current concepts in management of oral cancer--surgery. Oral Oncol; 2009 Apr-May;45(4-5):394-401
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery is the most well established mode of initial definitive treatment for a majority of oral cancers.
  • The factors that affect choice of treatment are related to the tumor and the patient.
  • Primary site, location, size, proximity to bone, and depth of infiltration are factors which influence a particular surgical approach.
  • Tumors that approach or involve the mandible require specific understanding of the mechanism of bone involvement.
  • The radial forearm free flap provides excellent soft tissue and lining for soft tissue defects in the oral cavity.
  • Over the course of the past thirty years there has been improvement in the overall survival of patients with oral carcinoma largely due to the improved understanding of the biology of local progression, early identification and treatment of metastatic lymph nodes in the neck, and employment of adjuvant post-operative radiotherapy or chemoradiotherapy.
  • The role of surgery in primary squamous cell carcinomas in other sites in the head and neck has evolved with integration of multidisciplinary treatment approaches employing chemotherapy and radiotherapy either sequentially or concurrently.
  • Similarly, the role of the surgeon is essential throughout the life history of a patient with a malignant neoplasm in the head and neck area, from initial diagnosis through definitive treatment, post-treatment surveillance, management of complications, rehabilitation of the sequelae of treatment, and finally for palliation of symptoms.
  • [MeSH-minor] Antineoplastic Protocols. Bone Neoplasms / surgery. Combined Modality Therapy. Head and Neck Neoplasms / surgery. Humans. Patient Selection. Reconstructive Surgical Procedures. Skin Neoplasms / surgery. Skull Base Neoplasms / surgery. Soft Tissue Neoplasms / surgery. Surgical Flaps. Treatment Outcome


9. Oechsle K, Lorch A, Honecker F, Kollmannsberger C, Hartmann JT, Boehlke I, Beyer J, Bokemeyer C: Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor. Oncology; 2010;78(1):47-53
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor.
  • OBJECTIVES: We investigated the pattern of relapse after chemotherapy in patients with high-risk germ cell tumor (GCT) to critically review common follow-up procedures including close monitoring of serum tumor markers and radiologic procedures.
  • METHODS: 645 patients received first-line (434 patients) or salvage platinum-based (211 patients) high-dose chemotherapy in three multicenter trials.
  • Retrospective analysis comprised 77 patients after first-line and 61 after salvage chemotherapy, who had achieved at least a partial remission but progressed afterwards.
  • RESULTS: At relapse, 24% of the patients presented with an isolated elevation in serum tumor markers, 26% with pathologic radiologic confirmation with negative tumor markers, and 42% with elevated tumor markers and radiologically confirmed progression.
  • Relapse pattern did not correlate with tumor marker status or metastasis location prior to chemotherapy, line of chemotherapy, response status after chemotherapy or time point of relapse.
  • CONCLUSION: In high-risk GCT patients, relapse after chemotherapy is detected either by tumor marker elevation alone, radiologic imaging alone or both, in one third each.
  • Close monitoring including serum tumor markers, radiologic imaging and clinical examination appears warranted within the first 2 years.
  • [MeSH-major] Biomarkers, Tumor / blood. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Germ Cell and Embryonal / diagnosis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Humans. Middle Aged. Platinum Compounds. Retrospective Studies. Young Adult

  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20215785.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Platinum Compounds; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Dürr HR, Müller PE, Hiller E, Maier M, Baur A, Jansson V, Refior HJ: Malignant lymphoma of bone. Arch Orthop Trauma Surg; 2002 Feb;122(1):10-6
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma of bone.
  • Malignant lymphoma of bone is rare.
  • In many cases, its diagnosis is delayed because of unspecific clinical signs and equivocal radiographs.
  • Therapy in general is multimodal, including surgery and radio- and chemotherapy.
  • Our objective was to demonstrate the clinical and radiological aspects of the lesion to optimize diagnostic approaches and to evaluate treatment and prognostic factors.
  • Thirty-six patients with malignant lymphoma of bone who were surgically treated over a 15-year-period were retrospectively reviewed.
  • Seventeen of them showed a singular bone non-Hodgkin's lymphoma (NHL) which was classified as primary lymphoma of the bone (PLB).
  • In 13 cases, dissemination of the disease with multiple bone or visceral involvement was apparent (dNHL).
  • Six patients suffered from bone involvement due to Hodgkin's disease (HD).
  • Surgical treatment was indicated for diagnostic reasons or complications due to the disease.
  • Radiation and chemotherapy were part of the oncological treatment.
  • The main symptom in malignant bone lymphoma in 33 patients was pain, with an average duration of 8 months.
  • In the secondary cases, bone involvement appeared on average 57 months after the initial diagnosis.
  • Soft-tissue involvement was seen in 71% of cases (PLB 80%, dNHL 73%, HD 40%) and was the primary diagnostic sign associated with this disease.
  • Multiple vs solitary bone involvement was the most significant factor in the prognosis.
  • No correlation was found between gender, age, location, or histological subtypes and survival.
  • Bone involvement in NHL appears late in the extraskeletal disease.
  • The clinical appearance is nonspecific, and the delay between the onset of symptoms and diagnosis is often long.
  • One of the major radiologic signs is the existence of a soft-tissue tumor surrounding the bone with little or no bone involvement on plain films.
  • Treatment generally is conservative, based on the stage of the disease.
  • Local radiation with or without systemic chemotherapy should be used.
  • The long-term survival is favorable, but dependent on the stage of the disease and the amount of bone involvement.
  • [MeSH-major] Bone Neoplasms / pathology. Bone Neoplasms / therapy. Hodgkin Disease / pathology. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Orthopedic Procedures / methods. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11995873.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


11. Harb WJ, Luna MA, Patel SR, Ballo MT, Roberts DB, Sturgis EM: Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension. Head Neck; 2007 Aug;29(8):731-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension.
  • Thus, we determined whether clinical characteristics and treatment were associated with recurrence and survival rates in patients with SS of the head and neck.
  • METHODS: We retrospectively identified patients with a pathologic diagnosis of SS of the head and neck at our institution (a large tertiary comprehensive cancer center) and compared recurrence and survival rates by clinical characteristics and treatment.
  • RESULTS: Forty patients with SS of the head and neck were identified from 1945 to 2004 (first case in 1968), representing <5% of all head and neck sarcomas seen at our institution during this time period.
  • Higher disease-specific and overall survival rates were associated with upper aerodigestive tract location, tumors of < or =5 cm, and tumors did not extend into bone.
  • Patients treated with surgery and adjuvant radiotherapy had higher survival and lower recurrence rates than did those treated with surgery alone or a combination of surgery, radiotherapy, and chemotherapy.
  • CONCLUSIONS: SS of the head and neck is extremely rare, and our results should be viewed with caution given the relatively small group size and treatment over a 36-year period.
  • Survival rates were associated with tumor location, size, and extension.
  • Treatment of SS of the head and neck should be directed toward complete surgical resection.
  • Given the known sensitivity of SS to contemporary chemotherapy, a multimodality approach should be considered in the perioperative setting, especially in high risk patients.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology. Sarcoma, Synovial / mortality. Sarcoma, Synovial / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Linear Models. Male. Medical Records. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Texas / epidemiology. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274049.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Weis J, Ciray I, Ericsson A, Lindman H, Aström G, Ahlström H, Hemmingsson A: Spectroscopic imaging of bone marrow composition in vertebral bodies. MAGMA; 2001 Aug;13(1):15-8
Hazardous Substances Data Bank. Water .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectroscopic imaging of bone marrow composition in vertebral bodies.
  • The bone marrow fat/water ratios were evaluated in the same location before and after chemotherapy treatment.
  • The fat/water ratios showed a significant increase as a consequence of the bone marrow degradation process due to chemotherapy.
  • [MeSH-major] Bone Marrow / pathology. Bone Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Protons. Spectrophotometry / methods. Spine / pathology
  • [MeSH-minor] Adipose Tissue / pathology. Breast Neoplasms / pathology. Female. Humans. Middle Aged. Neoplasm Metastasis. Water

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest Radiol. 1987 Sep;22(9):741-6 [3679764.001]
  • [Cites] Radiology. 1988 Sep;168(3):679-93 [3043546.001]
  • [Cites] MAGMA. 1997 Sep;5(3):201-12 [9351024.001]
  • [Cites] Magn Reson Imaging. 1990;8(6):779-89 [2266805.001]
  • [Cites] Magn Reson Imaging. 1991;9(4):509-15 [1664016.001]
  • [Cites] Radiology. 1991 Jun;179(3):615-21 [2027962.001]
  • [Cites] Magn Reson Med. 1994 Oct;32(4):470-5 [7997112.001]
  • [Cites] Magn Reson Imaging. 1997;15(7):823-37 [9309613.001]
  • [Cites] Magn Reson Med. 1992 Aug;26(2):207-17 [1513248.001]
  • [Cites] Magn Reson Med. 1987 Jul;5(1):32-46 [3309543.001]
  • [Cites] Magn Reson Imaging. 1988 Jul-Aug;6(4):355-68 [3054380.001]
  • [Cites] Magn Reson Med. 1993 Apr;29(4):465-9 [8464362.001]
  • [Cites] Magn Reson Med. 1999 May;41(5):904-8 [10332872.001]
  • [Cites] Radiology. 1988 Dec;169(3):799-804 [3187003.001]
  • (PMID = 11410392.001).
  • [ISSN] 0968-5243
  • [Journal-full-title] Magma (New York, N.Y.)
  • [ISO-abbreviation] MAGMA
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protons; 059QF0KO0R / Water
  •  go-up   go-down


13. Wafa H, Grimer RJ: Surgical options and outcomes in bone sarcoma. Expert Rev Anticancer Ther; 2006 Feb;6(2):239-48
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical options and outcomes in bone sarcoma.
  • Bone sarcomas are challenging to treat.
  • The primary goal of treatment is local control of the disease while, if possible, achieving salvage of the limb and its function.
  • There is no ideal method of reconstruction in limb-salvage surgery but the choice of the method of reconstruction should be individualized based upon many factors including the patient's age, the extent and location of the tumor, the wishes of the patient, and the availability of surgical facilities and expertise, as well as the cost of the procedure.
  • The surgical management of bone sarcomas is a real challenge to the orthopedic surgeon, owing to the diversity of sites in which tumors arise, combined with the extension of the tumor into adjacent soft tissues and their proximity, in many cases, to major neurovascular structures.
  • There have been dramatic improvements in survival for patients with osteosarcoma and Ewing's sarcoma in the past 30 years owing to increasing effectiveness of chemotherapy.
  • This, along with developments in imaging techniques (magnetic resonance imaging in particular) has led to earlier diagnosis and more accurate preoperative staging.
  • Whilst traditional treatment for bone tumors used to be amputation, advances in surgical techniques have made limb-salvage procedures a valid alternative method of treatment to amputation in 80-85% of patients with primary bone sarcomas.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage. Osteosarcoma / surgery
  • [MeSH-minor] Amputation. Decision Making. Humans. Neoplasm Recurrence, Local / surgery. Prosthesis Implantation. Reconstructive Surgical Procedures. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445376.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 73
  •  go-up   go-down


14. Chiewvit P, Danchaivijitr N, Sirivitmaitrie K, Chiewvit S, Thephamongkhol K: Does magnetic resonance imaging give value-added than bone scintigraphy in the detection of vertebral metastasis? J Med Assoc Thai; 2009 Jun;92(6):818-29
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does magnetic resonance imaging give value-added than bone scintigraphy in the detection of vertebral metastasis?
  • OBJECTIVE: To determine the role of Magnetic Resonance (MR) imaging for the investigation ofpatients with suspected metastasis to the spine by bone scintigraphy.
  • MATERIAL AND METHOD: Retrospectively reviewed with comparison was made between Technetium-99m Methylene Diphosphonate (99(m)Tc-MDP) bone scintigraphy and corresponding spine MR images in 48 cases of vertebral metastasis at Siriraj Hospital.
  • The intervals between bone scintigraphy and MR images did not exceed 1 month.
  • The authors studied between January 2005 and December 2006 Bone scintigraphy were performed with planar imaging of the entire body and MR imaging was performed with the 1.5 tesla and 3.0 tesla scanner using standard techniques with T1-, T2-weighted images and fat-suppressed T1-weighted images with intravenous administration of gadopentetate dimeglumine.
  • The MR imaging findings were studied: location (cervical or thoracic or lumbar or sacrum spine), number of lesions (solitary or multiple lesions), pattern of enhancement (homogeneous or inhomogeneous), involvement of spinal canal, compression of spinal cord, extradural extension, other incidental findings such as pulmonary metastasis, pleural effusion, lymphadenopathy The final diagnosis was confirmed clinically and followed-up for further management (radiation or surgery) or followed-up by MR imaging (1 month-16 months) and bone scintigraphy (5 months-12 months).
  • The result of bone scintigraphy and MR imaging is used to evaluate vertebral metastasis: in 44 lesions of bone scintigraphy positive for vertebral metastasis, 40/44 lesions (91%) which MR imaging reveal vertebral metastasis.
  • In 24 lesions of negative of bone scintigraphy for vertebral metastasis, the authors found that 14/24 lesions (58%) showed positive of vertebral metastasis from MR imaging.
  • In this group, the authors recommended a further investigation because 58% of negative bone scintigraphy lesions are depicted by only MR imaging.
  • CONCLUSION: The authors conclude that the MR imaging is more efficient than the bone scintigraphy in detecting vertebral metastasis, especially in the cases that bone scintigraphy are equivocal or negative for vertebral metastasis in high clinical suspicion.
  • Furthermore, MR imaging is important for the further treatment planning such as radiation therapy or systemic chemotherapy.
  • Although MR imaging is useful in the detection of early metastasis that are localized completely in the bone marrow cavity routinely bone scintigraphy remains that most cost-effective method for examination of the entire skeleton.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Diphosphonates. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / radionuclide imaging. Organotechnetium Compounds. Radionuclide Imaging. Retrospective Studies. Spinal Cord Compression. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530588.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Organotechnetium Compounds; 0 / technetium 99m methylene bisphosphonate
  •  go-up   go-down


15. Müller J: Impact of cancer therapy on the reproductive axis. Horm Res; 2003;59 Suppl 1:12-20
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of cancer therapy on the reproductive axis.
  • Cancer therapy includes surgery, chemotherapy and irradiation.
  • Depending on the diagnosis, the location of the neoplasm and the age of the patient, these treatment modalities may be given alone or in combination.
  • All forms of cancer therapy can affect the hypothalamic-pituitary-gonadal axis.
  • The sensitivity of germ cells to cancer therapy also differs between the sexes.
  • With regard to chemotherapy, the possible damage to the gonads is dependent on the total dose and type of agent given.
  • According to current knowledge, the hypothalamic-pituitary axis is not affected by conventional doses of chemotherapy.
  • The present review will focus on the late effects of cancer therapy in children and young adults with acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, brain tumour, Hodgkin's lymphoma or Wilms' tumour, including the adverse effects of bone marrow transplantation.
  • [MeSH-major] Hypothalamo-Hypophyseal System / drug effects. Hypothalamo-Hypophyseal System / radiation effects. Neoplasms / complications. Neoplasms / therapy. Ovary / drug effects. Ovary / radiation effects. Testis / drug effects. Testis / radiation effects
  • [MeSH-minor] Adolescent. Age Factors. Antineoplastic Agents / adverse effects. Bone Marrow Transplantation / adverse effects. Child. Female. Gonadal Steroid Hormones / blood. Humans. Male. Radiotherapy / adverse effects. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12566715.001).
  • [ISSN] 0301-0163
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Gonadal Steroid Hormones
  • [Number-of-references] 70
  •  go-up   go-down


16. Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, Reichardt P, Jürgens H, Gadner H, Bielack SS, Cooperative German-Austrian-Swiss Osteosarcoma Study Group: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol; 2003 May 15;21(10):2011-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To determine demographic data and define prognostic factors for long-term outcome in patients presenting with high-grade osteosarcoma of bone with clinically detectable metastases at initial presentation.
  • PATIENTS AND METHODS: Of 1,765 patients with newly diagnosed, previously untreated high-grade osteosarcomas of bone registered in the neoadjuvant Cooperative Osteosarcoma Study Group studies before 1999, 202 patients (11.4%) had proven metastases at diagnosis and therefore were enrolled onto an analysis of demographic-, tumor-, and treatment-related variables, response, and survival.
  • The intended therapeutic strategy included pre- and postoperative multiagent chemotherapy as well as aggressive surgery of all resectable lesions.
  • Actuarial overall survival rates at 5 and 10 (same value for 15) years were 29% (SE = 3%) and 24% (SE = 4%), respectively.
  • In univariate analysis, survival was significantly correlated with patient age, site of the primary tumor, number and location of metastases, number of involved organ systems, histologic response of the primary tumor to preoperative chemotherapy, and completeness and time point of surgical resection of all tumor sites.
  • However, after multivariate Cox regression analysis, only multiple metastases at diagnosis (relative hazard rate [RHR] = 2.3) and macroscopically incomplete surgical resection (RHR = 2.4) remained significantly associated with inferior outcomes.
  • CONCLUSION: The number of metastases at diagnosis and the completeness of surgical resection of all clinically detected tumor sites are of independent prognostic value in patients with proven primary metastatic osteosarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cisplatin / administration & dosage. Clinical Trials as Topic / statistics & numerical data. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Europe. Female. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Neoadjuvant Therapy. Neoplasm Metastasis. Prognosis. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2004 Dec 15;22(24):5017; author reply 5017-8 [15611520.001]
  • (PMID = 12743156.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; COSS-86 protocol
  •  go-up   go-down


17. Hauben EI, Bielack S, Grimer R, Jundt G, Reichardt P, Sydes M, Taminiau AH, Hogendoorn PC: Clinico-histologic parameters of osteosarcoma patients with late relapse. Eur J Cancer; 2006 Mar;42(4):460-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary high-grade intramedullary osteosarcoma of the extremities is a clinically aggressive bone tumour.
  • There is an ongoing effort to further improve efficacy of neo-adjuvant chemotherapy and reduce chemotoxicity by trying to identify osteosarcoma patients who are at risk of treatment failure as well as to identify those who can do with less chemotherapy.
  • In only 5% of patients, first distant metastasis or local relapse occurs 5 years or more after initial treatment for osteosarcoma.
  • Patients and physicians can therefore easily erroneously consider a patient with osteosarcoma cured if he or she is disease-free for more than 5 years following diagnosis and treatment.
  • To investigate if these rare late relapsing patients are characterised by specific clinico-pathological features, we examined clinical and histological variables of late relapse (first local recurrence or metastasis 5 years or more after initial diagnosis) out of a total of 2,243 patients, with a special interest in the histological osteosarcoma subtype.
  • In total, 33 patients had a documented relapse 5 years or more after diagnosis.
  • Half of the patients had good response (>or=90% necrosis) to pre-operative chemotherapy and the other half a poor response (<90% necrosis) and late relapses seemed to be more frequently proportionately in those who had a good initial response to chemotherapy.
  • Although not statistically significant, there was a trend for patients with a chondroblastic subtype of osteosarcoma, or a location in the tibia or fibula, to have a higher risk for late relapse.
  • [MeSH-major] Bone Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426841.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U122861384
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Rodríguez-Arias CA, Lobato RD, Millán JM, Lagares A, de la Lama A, Alén JF: Parosteal osteosarcoma of the skull. Neurocirugia (Astur); 2001 Dec;12(6):521-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parosteal osteosarcoma of the skull is a distinct surface bone tumor, with a better prognosis than conventional osteosarcoma.
  • The most common location is on the surface of the distal femur which accounts for 46-66% of the cases.
  • We describe the case of a man who developed a parosteal osteosarcoma arising from the occipital bone with extension to the parietal bone.
  • The patient was operated and had a complete tumor resection.
  • [MeSH-major] Occipital Bone / pathology. Osteosarcoma, Juxtacortical / pathology. Parietal Bone / pathology. Skull Neoplasms / pathology
  • [MeSH-minor] Cerebral Angiography. Chemotherapy, Adjuvant. Combined Modality Therapy. Craniotomy. Diagnosis, Differential. Disease Progression. Fatal Outcome. Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Osteosarcoma / diagnosis. Osteosarcoma / drug therapy. Osteosarcoma / pathology. Osteosarcoma / radiotherapy. Osteosarcoma / secondary. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11787402.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 16
  •  go-up   go-down


19. Castel V, Tovar JA, Costa E, Cuadros J, Ruiz A, Rollan V, Ruiz-Jimenez JI, Perez-Hernández R, Cañete A: The role of surgery in stage IV neuroblastoma. J Pediatr Surg; 2002 Nov;37(11):1574-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/PURPOSE: The importance of primary tumor resection in stage IV neuroblastoma is controversial.
  • Age, sex, location of the tumor, type of metastases, time of resection (initial or delayed), extension of resection, surgical complications, pathology, N-myc and Shimada classification results, relapses, and outcome were studied.
  • After diagnosis, children received induction chemotherapy followed by delayed surgery and autologous stem cell transplantation or maintenance chemotherapy.
  • Seventy-six were older than one year, and in 78 the primary tumor was abdominal.
  • Bone was the most common metastatic site followed by bone marrow.
  • Mean survival rate time was 50 months.
  • EFS rate for infants was 0.56, but, again, there was no difference in relation to the type of resection.
  • CONCLUSIONS: Biopsies of stage IV neuroblastoma allow safe assessment of N-myc and other biological factors on tumor tissue.
  • Delayed surgery after chemotherapy is performed with a low rate of complications, achieving a good local control of disease.
  • N-myc-amplified tumors have higher local relapse rates than nonamplified and therefore would need more intensive local treatment.
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / mortality. Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Biopsy, Needle. Bone Marrow Neoplasms / secondary. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Lymphatic Metastasis. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / mortality. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12407542.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Babiera GV, Rao R, Feng L, Meric-Bernstam F, Kuerer HM, Singletary SE, Hunt KK, Ross MI, Gwyn KM, Feig BW, Ames FC, Hortobagyi GN: Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol; 2006 Jun;13(6):776-82
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor.
  • BACKGROUND: Currently, therapy for breast cancer patients with stage IV disease and an intact primary tumor is metastasis directed; the primary tumor is treated only when it causes symptoms.
  • METHODS: We reviewed the records of all breast cancer patients treated at our institution between 1997 and 2002 who presented with stage IV disease and an intact primary tumor.
  • Information collected included demographics, tumor characteristics, site(s) of metastases, type/date of operation, use of radiotherapy, chemotherapy and hormonal therapy, disease progression (time to progression and location of progression) in the first year after diagnosis, and last follow-up.
  • RESULTS: Of 224 patients identified, 82 (37%) underwent surgical extirpation of the primary tumor (segmental mastectomy in 39 [48%] and mastectomy in 43 [52%]), and 142 (63%) were treated without surgery.
  • The median follow-up time was 32.1 months.
  • CONCLUSIONS: Removal of the intact primary tumor for breast cancer patients with synchronous stage IV disease is associated with improvement in metastatic progression-free survival.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Combined Modality Therapy. Disease Progression. Female. Humans. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2006 Jun;13(6):759-60 [16604472.001]
  • [CommentIn] Ann Surg Oncol. 2007 Apr;14(4):1519-20 [17225978.001]
  • (PMID = 16614878.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Zentar A, Sall I, Ali AA, Bouchentouf SM, Quamous M, Chahdi H, Hajjouji A, Fahssi M, El Kaoui H, Al Bouzidi A, Marjani M, Sair K, Bousselmame N: Sacral hemangiopericytoma involving the retrorectal space: report of a case. Surg Today; 2009;39(4):344-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A primary hemangiopericytoma (HP) of the bone is rare, because the vast majority of these tumors arise in soft tissue.
  • The difficult diagnosis of HP and the surgical strategy was chosen according to the location of the lesion in the sacrum and retrorectal space.
  • The value of chemotherapy is still doubtful, although patients with high-grade tumors or metastatic spread seem to gain substantial benefit.
  • Due to the often unpredictable behavior of this neoplasm, extended follow-up is strongly recommended.
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Langenbecks Arch Surg. 2000 Apr;385(3):207-12 [10857492.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1958 Jun 25;33(13):347-52 [13601937.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1746-51 [12365023.001]
  • [Cites] Hum Pathol. 1976 Jan;7(1):61-82 [1244311.001]
  • [Cites] Hum Pathol. 1991 Jan;22(1):84-91 [1985083.001]
  • [Cites] Ann Surg. 1974 Feb;179(2):128-32 [4359454.001]
  • [Cites] Histopathology. 1988 Apr;12(4):405-14 [3131230.001]
  • [Cites] Cancer. 1975 Dec;36(6):2232-44 [1203874.001]
  • [Cites] Dis Colon Rectum. 2005 Oct;48(10):1964-74 [15981068.001]
  • [Cites] Ann Surg. 1942 Jul;116(1):26-33 [17858068.001]
  • [Cites] Arch Pathol. 1969 Dec;88(6):653-63 [4311513.001]
  • [Cites] Surg Today. 2008;38(8):761-4 [18668324.001]
  • [Cites] Br J Surg. 2008 Feb;95(2):214-21 [17933000.001]
  • [Cites] Int J Colorectal Dis. 1993 Sep;8(3):134-8 [8245668.001]
  • [Cites] Cancer. 1988 Aug 15;62(4):848-59 [3293766.001]
  • [Cites] Eur Radiol. 2002 Jan;12(1):85-9 [11868080.001]
  • (PMID = 19319645.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Grimer RJ, Gosheger G, Taminiau A, Biau D, Matejovsky Z, Kollender Y, San-Julian M, Gherlinzoni F, Ferrari C: Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer; 2007 Sep;43(14):2060-5
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular there remains uncertainty about the value of chemotherapy for this condition.
  • We obtained data on 337 patients from nine European centres with this rare condition, with details on patients, treatment and outcome which were then analysed in an attempt to identify prognostic features.
  • Twenty-nine percent of patients with a long bone tumour had a pathological fracture.
  • 71 patients (21%) had metastases at the time of diagnosis and these patients had a median survival of 5 months with a 10% chance of survival at 2 years.
  • For the 266 patients without metastases at diagnosis, 254 underwent surgery with 79% having limb salvage.
  • Thirty-one percent of these 266 patients had chemotherapy with 47% of those under 60 receiving it.
  • In this group of 266 patients, overall survival was 28% at 10 years and poor prognostic factors were the presence of a pathological fracture at diagnosis, a pelvic location and increasing age.
  • We did not find that the histological subtype, size of the tumour or the use of chemotherapy significantly affected outcome.
  • Surgery with clear margins remains the principal treatment for this condition.
  • Further use of chemotherapy should be within a trial or treatment protocol.
  • [MeSH-major] Bone Neoplasms / mortality. Chondrosarcoma / mortality
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Europe / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17720491.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Yin M, Ishikawa K, Honda K, Arakawa T, Harabuchi Y, Nagabashi T, Fukuda S, Taira A, Himi T, Nakamura N, Tanaka K, Ichinohe M, Shinkawa H, Nakada Y, Sato H, Shiga K, Kobayashi T, Watanabe T, Aoyagi M, Ogawa H, Omori K: Analysis of 95 cases of squamous cell carcinoma of the external and middle ear. Auris Nasus Larynx; 2006 Sep;33(3):251-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ninety five cases of patients from 10 institutions were reviewed on their age and sex distribution, initial complaints, stages, tumor locations, treatments, and outcomes.
  • SCC in stages I and II was susceptible to each therapeutic strategy with a 5-year survival of 100%.
  • Operation combined with radiotherapy and/or chemotherapy was the major treatment for stages III and IV SCC, while radiotherapy and chemotherapy were applied mainly for those who had been considered inappropriate for operation.
  • The overall survival was 67.2% for stage III and 29.5% for stage IV, and operation with pathologically tumor free margin could improve the survival to 72.7% when combined with radio- and chemotherapy.
  • Stage, completeness of operation with tumor free margin, recurrence, and metastasis have significant influence on survival.
  • Early diagnosis and treatment were important because SCC in the earlier stage is susceptible to be cured.
  • For tumors of advanced stage, operation should be performed with pathologically tumor free margin, and operation combined with radiotherapy and chemotherapy could improve the survival.
  • Tumor stage adds more influence on survival than its location.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Earache. Facial Paralysis. Female. Hearing Loss. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Prognosis. Retrospective Studies. Survival Analysis. Temporal Bone / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16431060.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol; 2002 Feb 01;20(3):776-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: A total of 1,702 consecutive newly diagnosed patients with high-grade osteosarcoma of the trunk or limbs registered into the neoadjuvant studies of the Cooperative Osteosarcoma Study Group before July 1998 were entered into an analysis of demographic, tumor-related, and treatment-related variables, response, and survival.
  • The intended therapeutic strategy included preoperative and postoperative chemotherapy with multiple agents as well as surgery of all operable lesions.
  • RESULTS: Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis.
  • Among the variables assessable at diagnosis, patient age (actuarial 10-year survival > or = 40, 41.6%; < 40, 60.2%; P =.012), tumor site (axial, 29.2%; limb, 61.7%; P <.0001), and primary metastases (yes, 26.7%; no, 64.4%; P <.0001), and for extremity osteosarcomas, also size (> or = one third, 52.5%; < one third, 66.7%; P <.0001) and location within the limb (proximal, 49.3%; other, 63.9%; P <.0001), had significant influence on outcome.
  • Two additional important prognostic factors were treatment related: response to chemotherapy (poor, 47.2%; good, 73.4%; P <.0001) and the extent of surgery (incomplete, 14.6%; macroscopically complete, 64.8%; P <.0001).
  • CONCLUSION: Tumor site and size, primary metastases, response to chemotherapy, and surgical remission are of independent prognostic value in osteosarcoma.
  • [MeSH-major] Bone Neoplasms / mortality. Bone Neoplasms / therapy. Osteosarcoma / mortality. Osteosarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2002 Feb 1;20(3):627-9 [11821441.001]
  • [CommentIn] J Clin Oncol. 2002 Jun 15;20(12):2910; author reply 2910-1 [12065572.001]
  • (PMID = 11821461.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Meyers PA, Levy AS: Ewing's sarcoma. Curr Treat Options Oncol; 2000 Aug;1(3):247-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with Ewing's sarcoma should be transferred to a comprehensive cancer center for evaluation and management when the diagnosis is suspected.
  • Proper biopsy technique is essential to preserve all therapeutic options, including limb preservation surgery.
  • In addition to conventional histologic examination, biopsy tissue must be obtained for molecular biology studies.
  • Demonstration of the consistent chromosomal translocation associated with Ewing's sarcoma is essential for diagnosis, and the specific type of fusion transcript has prognostic implications.
  • Treatment must be intimately coordinated among oncologist, surgeon, and radiation oncologist.
  • Successful treatment requires systemic, multi-agent chemotherapy and local control.
  • The primary tumor can be treated with surgery, radiation therapy, or a combination of the two.
  • The choice of modality should be dictated by the age of the patient, location of the primary tumor, functional consequences of the intervention, and concern about late effects, especially secondary malignancy.
  • Treatment of the patient who presents with clinically detectable metastatic disease or who relapses after initial therapy remains unsatisfactory and controversial.
  • [MeSH-major] Bone Neoplasms / therapy. Sarcoma, Ewing / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local / therapy. Prognosis. Radiotherapy. Survival Rate

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2818-25 [8874344.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Aug;97(1):12-9 [9242212.001]
  • [Cites] Diagn Mol Pathol. 1993 Sep;2(3):141-6 [8287228.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1407-12 [1517783.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Jul;5(1):30-4 [1384659.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):222-7 [10508522.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2818-25 [2025847.001]
  • [Cites] Med Pediatr Oncol. 1999 Aug;33(2):65-70 [10398178.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1482-8 [8101562.001]
  • [Cites] Cancer Treat Rep. 1984 May;68(5):703-10 [6722828.001]
  • [Cites] N Engl J Med. 1994 Aug 4;331(5):294-9 [8022439.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2796-804 [7595741.001]
  • [Cites] J Bone Joint Surg Am. 1998 Jul;80(7):1020-33 [9698007.001]
  • (PMID = 12057167.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 19
  •  go-up   go-down


26. Iyigun T, Ciloglu U, Ariturk C, Civelek A, Tosun R: Recurrent cardiac metastasis of primary femoral osteosarcoma: a case report. Heart Surg Forum; 2010 Oct;13(5):E333-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on the collaborative decision of the oncology and cardiovascular surgery clinics, surgery was performed and the patient was discharged without any problems.
  • According to the recommendation of the oncology clinic, chemotherapy was postponed for 6 months after surgery.
  • Based on the collaborative decision, chemotherapy was initiated and in 2 months the size of the recurrent tumors had diminished.
  • The patient is still under the care of the oncology and cardiovascular surgery clinics and continuing her chemotherapy regimen.
  • The location of the metastasis and the characteristics of the primary tumor determine the treatment modality.
  • In some previously published reports, various treatment choices have been described.
  • [MeSH-major] Bone Neoplasms / pathology. Femur. Heart Neoplasms / secondary. Neoplasm Recurrence, Local. Osteosarcoma / secondary
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Diagnosis, Differential. Echocardiography. Female. Follow-Up Studies. Heart Ventricles. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20961837.001).
  • [ISSN] 1522-6662
  • [Journal-full-title] The heart surgery forum
  • [ISO-abbreviation] Heart Surg Forum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Okada K, Hasegawa T, Nishida J, Ogose A, Tajino T, Osanai T, Yanagisawa M, Hatori M: Osteosarcomas after the age of 50: a clinicopathologic study of 64 cases--an experience in northern Japan. Ann Surg Oncol; 2004 Nov;11(11):998-1004
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Clinicopathologic features were analyzed in 645 patients with osteosarcoma who were registered at the Tohoku Musculoskeletal Tumor Society and National Cancer Center in Tokyo between 1972 and 2002.
  • The most common location was the distal femur (n = 13), followed by the pelvis (n = 10), proximal femur (n = 9), and proximal fibula (n = 6).
  • Preoperative chemotherapy was given to 22 patients, but the effect was poor in 18 cases (82%).
  • Multivariate analysis showed initial pulmonary metastasis, axial tumor location, and larger tumors as significant prognostic factors.
  • Careful radiological examination and biopsy are mandatory for correct diagnosis.
  • Current systemic chemotherapy is not effective for this age group.
  • Alternative treatment strategies should be considered.
  • [MeSH-major] Bone Neoplasms / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Age of Onset. Aged. Combined Modality Therapy. Female. Humans. Japan. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Metastasis. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15525829.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Karcioglu ZA, Hadjistilianou D, Rozans M, DeFrancesco S: Orbital rhabdomyosarcoma. Cancer Control; 2004 Sep-Oct;11(5):328-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although rhabdomyosarcoma (RMS) is a rare tumor among the entire group of mesenchymal malignancies, it is a relatively common lesion and significant challenge for the ocular oncologist in terms of its diagnosis and management.
  • The tumor has predilection for the superior nasal quadrant of the orbit.
  • The clinical manifestations depend on the location of the tumor within the orbit and its rate of growth.
  • The common histopathologic types are embryonal and alveolar varieties.
  • CT and MR imaging are important in the evaluation of this tumor.
  • Particular attention should be placed on the bone invasion and extension of the tumor into the intracranial cavity and paranasal sinuses.
  • Treatment usually consists of a combination of chemotherapy and radiation therapy following excisional biopsy.
  • CONCLUSIONS: Survival of orbital RMS has improved due to advances in chemotherapy and radiotherapy.
  • [MeSH-major] Eye Neoplasms / diagnosis. Eye Neoplasms / therapy. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Neoplasm Staging. Ophthalmologic Surgical Procedures / methods. Prognosis. Radiotherapy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15377992.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 42
  •  go-up   go-down


29. Amo Trillo V, Vera García P, Pinto I, Olmedo Martín R, Romero Blasco B: [Extramedullary plasmacytoma of the colon]. Gastroenterol Hepatol; 2007 May;30(5):277-9
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No other location was affected (including bone marrow).
  • Diagnosis of plasmacytoma of the colon was made.
  • [MeSH-major] Plasmacytoma / diagnosis. Sigmoid Neoplasms / diagnosis
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonoscopy. Combined Modality Therapy. Diverticulum / complications. Fatal Outcome. Gastrointestinal Hemorrhage / etiology. Hemorrhoids / complications. Humans. Lymphatic Metastasis. Male. Melphalan / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Rectum

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493438.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; Q41OR9510P / Melphalan
  •  go-up   go-down


30. Cohen L, Dank G, Milgram J: Non-skeletal multicentric chondrosarcoma in the hindlimb of a dog. J Small Anim Pract; 2010 Oct;51(10):553-7
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple soft tissue masses were palpable within the hindlimb muscles.
  • A tentative diagnosis of sarcoma was made on fine needle aspiration.
  • A computed tomography scan of the hindlimb and thorax confirmed the presence and location of the masses, none of which were associated with the bones of the hindlimb.
  • A diagnosis of chondrosarcoma was confirmed on histopathology with a final diagnosis of extraskeletal chondrosarcoma.
  • A high, hindlimb amputation was performed, and chemotherapy was initiated.
  • [MeSH-major] Bone Neoplasms / veterinary. Chondrosarcoma / veterinary. Dog Diseases / pathology
  • [MeSH-minor] Amputation / veterinary. Animals. Dogs. Female. Hindlimb. Lameness, Animal / pathology. Lameness, Animal / surgery. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 British Small Animal Veterinary Association.
  • (PMID = 21029099.001).
  • [ISSN] 1748-5827
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Lee JA, Kim DH, Lim JS, Koh JS, Kim MS, Kong CB, Song WS, Cho WH, Lee SY, Jeon DG: Soft-tissue Ewing sarcoma in a low-incidence population: comparison to skeletal Ewing sarcoma for clinical characteristics and treatment outcome. Jpn J Clin Oncol; 2010 Nov;40(11):1060-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue Ewing sarcoma in a low-incidence population: comparison to skeletal Ewing sarcoma for clinical characteristics and treatment outcome.
  • OBJECTIVE: Due to the low incidence, treatments for Korean soft tissue Ewing sarcoma patients have been heterogeneous, and reported data are limited.
  • In this study, we retrospectively analyzed soft tissue Ewing cases treated at our institution.
  • METHODS: We analyzed the clinicopathologic characteristics and treatment outcome of soft tissue Ewing sarcoma patients and compared with those of skeletal cases.
  • RESULTS: Twenty-seven soft tissue Ewing sarcoma cases were evaluated.
  • Patients with soft tissue Ewing sarcoma were older than patients with skeletal tumors (P = 0.03), and tended to have metastasis at diagnosis (P = 0.12).
  • However, sex ratios, pathologies, tumor volumes, and histologic response to preoperative chemotherapy were not different in the two groups.
  • The 5-year overall survival (49.0%) and event-free survival (45.6%) of soft tissue Ewing sarcoma patients were similar to those of skeletal tumor patients (51.8% and 46.0%, respectively).
  • Presence of metastasis at diagnosis and poor histologic response to preoperative chemotherapy were associated with an adverse outcome for both groups.
  • Similar to skeletal tumors, central tumor location, pathology and tumor volume tended to be related to the survival of soft tissue Ewing sarcoma.
  • However, age and the use of a modality other than surgery to achieve local control did not influence the survival of soft tissue Ewing sarcoma patients.
  • [MeSH-major] Bone Neoplasms / pathology. Bone Neoplasms / therapy. Sarcoma / pathology. Sarcoma / therapy. Sarcoma, Ewing / pathology. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Incidence. Male. Middle Aged. Musculoskeletal System / pathology. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult


32. Fernández Y, Bernabeu-Wittel M, García-Morillo JS: Kaposiform hemangioendothelioma. Eur J Intern Med; 2009 Mar;20(2):106-13
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposiform hemangioendothelioma (KHE) is a rare, locally aggressive vascular neoplasm that mainly occurs during childhood.
  • It generally originates on the skin, usually affecting deeper tissue by infiltrative growth.
  • Although visceral involvement is very uncommon, several cases with bone, retroperitoneal, or mediastinal involvement have been described.
  • Several factors are associated with the outcome of patients with KHE: accessibility to surgical excision, location (cutaneous versus visceral), size of tumoral mass, clinical response to interferon and glucocorticoids, and the absence of lymphangiomatosis and Kasabach-Merritt syndrome, may result in partial remissions.
  • On the other hand, bulk visceral masses lead to a 40-50% mortality rate, mainly due to progressive failure of the infiltrated organ(s), in spite of interferon, glucocorticoids, and combined chemotherapy.
  • In conclusion, the onset of a consumptive coagulopathy following the presence of a vascular tumor, in children as well as in older patients, should spark suspicion of KHE, among other entities.
  • [MeSH-major] Hemangioendothelioma / diagnosis. Hemangioendothelioma / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy. Vascular Neoplasms / diagnosis. Vascular Neoplasms / therapy

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • Genetic Alliance. consumer health - Kaposiform Hemangioendothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19327597.001).
  • [ISSN] 1879-0828
  • [Journal-full-title] European journal of internal medicine
  • [ISO-abbreviation] Eur. J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 87
  •  go-up   go-down


33. Yariş N, Kutluk T, Yalçin B, Akyüz C, Büyükpamukçu M: Nasal-paranasal-oronasopharyngeal lymphomas in childhood: the role of staging system on prognosis. Pediatr Hematol Oncol; 2000 Jul-Aug;17(5):345-53
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment results were analyzed to see the effects of the staging in NPONP lymphomas.
  • The Murphy staging system was used at diagnosis and all cases were restaged according to the TNM system: primary tumor, regional lymph node, and metastasis.
  • The survival rates were analyzed by grouping the patients according to the treatment and stages.
  • Treatment protocols were intensified in most of the early-stage disease treated with modified LSA2-L2 regimen and better survival rates were obtained in these patients.
  • The intensification of the treatment by using intrathecal treatment and doxorubicin in patients with early-stage disease at NPONP location seems effective.
  • It should be revised to predict the prognosis and decision-making for treatment.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Nose Neoplasms / diagnosis. Pharyngeal Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Neoplasms / secondary. Central Nervous System Neoplasms / secondary. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Daunorubicin / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Nasopharyngeal Neoplasms / diagnosis. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / pathology. Neoplasm Staging. Oropharyngeal Neoplasms / diagnosis. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / pathology. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / pathology. Prednisone / administration & dosage. Prognosis. Recurrence. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Hematol Oncol. 2000 Oct-Nov;17(7):517-20 [11033725.001]
  • (PMID = 10914044.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; LSA2-L2 protocol
  •  go-up   go-down


34. Thieblemont C, de la Fouchardière A, Coiffier B: Nongastric mucosa-associated lymphoid tissue lymphomas. Clin Lymphoma; 2003 Mar;3(4):212-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nongastric mucosa-associated lymphoid tissue lymphomas.
  • Nongastric mucosa-associated lymphoid tissue (MALT)-derived lymphomas arise from various extranodal locations and are usually related to a particular pathogenesis with a possible external (environmental or autoimmune) event inducing the disease.
  • The site of clinical presentation was related to the lymphoma location and was usually indolent.
  • Dissemination of the disease at diagnosis was noticed in 48% of cases because of the involvement of multiple mucosal sites (48%) or because of a nonmucosal site involvement such as bone marrow, spleen, or liver (52%).
  • Treatment recommendations for localized disease are based on surgery, local therapy, or chlorambucil.
  • For disseminated disease, treatment recommendations include chemotherapy with fludarabine or chlorambucil or chemotherapy with CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) in cases of large tumor mass
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Disease-Free Survival. Humans. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12672270.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 102
  •  go-up   go-down


35. Eyesan SU, Obalum DC, Onovo DO, Ketiku KK, Abdulkareem FB: Indications for ablative surgery in extremity musculoskeletal tumours. Nig Q J Hosp Med; 2009 Sep-Dec;19(4):206-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Surgical options for treatment of extremity musculoskeletal tumours include excision [limb sparing] surgery or amputation [limb ablation].
  • Data such as age, gender, presenting complaints, anatomic location of the tumour, clinical stage, type of ablative surgery and adjuvant treatment offered, histologic type of tumour, and treatment outcome were documented.
  • RESULTS: Nineteen patients had ablative surgery as a mode of treatment.
  • Seven patients [6 males and 1 female] refused ablative surgery and voluntarily discontinued treatment.
  • Most tumours were located in the lower limb and all patients that had ablative treatment presented with stage 3 or 4 disease.
  • Osteogenic sarcoma was the most common diagnosis, accounting for 4 cases [21.1%].
  • Six patients [31.6%] with non-malignant tumours had ablative surgery due to either late presentation or inaccurate preoperative diagnosis.
  • Adjuvant chemotherapy was prescribed for all patients.
  • [MeSH-major] Amputation / methods. Bone Neoplasms / surgery. Lower Extremity / surgery. Neoplasms, Bone Tissue / surgery. Upper Extremity / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Hospitals, Special. Humans. Male. Middle Aged. Neoplasm Staging. Nigeria. Orthopedics. Prospective Studies. Radiotherapy, Adjuvant. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20836332.001).
  • [ISSN] 0189-2657
  • [Journal-full-title] Nigerian quarterly journal of hospital medicine
  • [ISO-abbreviation] Nig Q J Hosp Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


36. Reiss-Zimmermann M, Hirsch W, Schuster V, Wojan M, Sorge I: Pyogenic osteomyelitis of the vertebral arch in children. J Pediatr Surg; 2010 Aug;45(8):1737-40
Hazardous Substances Data Bank. CLINDAMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The unusual location creates difficulties in distinguishing vertebral osteomyelitis from neoplasm and arthritic conditions.
  • Antibiotic therapy with or without surgical intervention provided successful management.
  • With the recurrence observed in 1 child, the most optimal treatment of this condition might still be unknown.
  • [MeSH-major] Lumbar Vertebrae / surgery. Osteomyelitis / diagnosis. Osteomyelitis / surgery. Spinal Diseases / diagnosis. Spinal Diseases / surgery
  • [MeSH-minor] Adolescent. Bone Marrow Diseases / diagnosis. Bone Marrow Diseases / radiography. Bone Marrow Diseases / surgery. Cefuroxime / therapeutic use. Child. Clindamycin / therapeutic use. Humans. Magnetic Resonance Imaging. Male. Preoperative Care / methods. Staphylococcal Infections / drug therapy. Staphylococcal Infections / radiography. Tomography, X-Ray Computed / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Osteomyelitis.
  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20713232.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3U02EL437C / Clindamycin; O1R9FJ93ED / Cefuroxime
  •  go-up   go-down






Advertisement